文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

间充质基质细胞联合体外膜氧合治疗急性呼吸窘迫综合征:绵羊随机对照试验

Combined Mesenchymal Stromal Cell Therapy and Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome. A Randomized Controlled Trial in Sheep.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01
一句话结论绵羊ARDS联合ECMO模型中,经支气管给予人源间充质基质细胞未改善氧合,且损害膜氧合器功能,不推荐在静脉-静脉ECMO期间安全使用。

该研究在14只绵羊中诱导ARDS并建立静脉-静脉ECMO,随机接受经支气管诱导多能干细胞来源的人间充质基质细胞(n=7)或无细胞载体对照(n=7),采用低潮气量通气及程序化血流动力学支持,监测24小时。结果显示hMSC组氧合无改善(PaO2/FiO2平均差=-146 mmHg;P=0.076),但肺损伤评分(平均差=-0.07;P=0.04)和BAL IL-8降低,血管升压药累积需求显著更低。然而hMSC组跨膜氧合器压力梯度显著升高,伴更多肺动脉血栓和氧合器纤维上黏附的hMSC。作者结论认为经支气管hMSC治疗可损害膜氧合器功能且不改善氧合,不推荐在静脉-静脉ECMO期间安全使用hMSC。

要点

  • 在绵羊ARDS联合静脉-静脉ECMO模型中,经支气管hMSC治疗未改善氧合(PaO2/FiO2平均差=-146 mmHg;P=0.076)。
  • hMSC组肺损伤评分平均差=-0.07(P=0.04)且BAL IL-8降低,血管升压药累积需求显著更低。
  • 尽管经支气管给药,hMSC组跨膜氧合器压力梯度显著升高,伴更多肺动脉血栓和氧合器纤维上黏附的hMSC。
  • 作者结论认为这些数据不推荐在静脉-静脉ECMO期间安全使用hMSC。

适用人群与场景

  • 14只绵羊诱导ARDS后建立静脉-静脉ECMO模型。

处置流程与药物剂量

  • ECMO期间采用低潮气量通气策略并给予程序化血流动力学支持,监测和支持24小时。

研究设计与关键结果

  • 研究类型:随机对照动物实验;样本量:14只绵羊;人群:ARDS联合静脉-静脉ECMO模型;干预:经支气管诱导多能干细胞来源的人间充质基质细胞(hMSC,n=7);对照:无细胞载体(n=7)。
  • 主要终点:hMSC未改善氧合(PaO2/FiO2平均差=-146 mmHg;P=0.076)或肺功能。
  • 关键次要终点:hMSC组肺损伤评分平均差=-0.07(P=0.04)和BAL IL-8降低;血管升压药累积需求显著更低。
  • 不良事件:hMSC组跨膜氧合器压力梯度显著升高,伴更多肺动脉血栓和氧合器纤维上黏附的hMSC。

证据类型、等级与局限

  • 证据类型:随机对照动物实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为这些数据不推荐在静脉-静脉ECMO期间安全使用hMSC。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Mesenchymal stromal cell (MSC) therapy is a promising intervention for acute respiratory distress syndrome (ARDS), although trials to date have not investigated its use alongside extracorporeal membrane oxygenation (ECMO). Recent preclinical studies have suggested that combining these interventions may attenuate the efficacy of ECMO.Objectives: To determine the safety and efficacy of MSC therapy in a model of ARDS and ECMO.Methods: ARDS was induced in 14 sheep, after which they were established on venovenous ECMO. Subsequently, they received either endobronchial induced pluripotent stem cell-derived human MSCs (hMSCs) (n = 7) or cell-free carrier vehicle (vehicle control; n = 7). During ECMO, a low Vt ventilation strategy was employed in addition to protocolized hemodynamic support. Animals were monitored and supported for 24 hours. Lung tissue, bronchoalveolar fluid, and plasma were analyzed, in addition to continuous respiratory and hemodynamic monitoring.Measurements and Main Results: The administration of hMSCs did not improve oxygenation (PaO2/FiO2 mean difference = -146 mm Hg; P = 0.076) or pulmonary function. However, histological evidence of lung injury (lung injury score mean difference = -0.07; P = 0.04) and BAL IL-8 were reduced. In addition, hMSC-treated animals had a significantly lower cumulative requirement for vasopressor. Despite endobronchial administration, animals treated with hMSCs had a significant elevation in transmembrane oxygenator pressure gradients. This was accompanied by more pulmonary artery thromboses and adherent hMSCs found on explanted oxygenator fibers.Conclusions: Endobronchial hMSC therapy in an ovine model of ARDS and ECMO can impair membrane oxygenator function and does not improve oxygenation. These data do not recommend the safe use of hMSCs during venovenous ECMO.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Millar JE, Bartnikowski N, Passmore MR, et al. Combined Mesenchymal Stromal Cell Therapy and Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome. A Randomized Controlled Trial in Sheep. Am J Respir Crit Care Med. 2020. PMID: 32293914. doi:10.1164/rccm.201911-2143OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。